Intervention: AZD3152/Sipavibart

NOVELLA

Russian Federation
|
2023-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • AZD3152/Sipavibart